Skip to main content
Clinical Trials/JPRN-UMIN000037327
JPRN-UMIN000037327
Completed
N/A

A pilot study for early evaluation and estimation of prognosis of patients with advanced and/or relapsed breast cancer by endocrine and/or CDK4/6 inhibitor combined therapy using estrogen receptor PET - A pilot study for breast cancer by endocrine and/or CDK4/6 inhibitor combined therapy using estrogen receptor PET

Saitama Medical University0 sites8 target enrollmentAugust 1, 2019
ConditionsBreast cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Saitama Medical University
Enrollment
8
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

We compared the values of the positive therapy response (RP) group (lesions with a decrease in the FDG SUVmax >=30% after treatment) and the negative therapy response (RN) group (lesions with a decrease in the FDG SUVmax <30%). The FES SUVmax was significantly different in both groups before (RPpre and RNpre) and after (RPpost and RNpost) treatment. The FES value was high before treatment and low after treatment. A decrease trend like FES changes was observed for the FDG SUVmax).

Registry
who.int
Start Date
August 1, 2019
End Date
September 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. patients with the serum fasting glucose level is more than 150mg/dL at the day of entry 2\. patients who entered to the other clinical trials 28 days before the day of entry

Outcomes

Primary Outcomes

Not specified

Similar Trials